# Riddley v. Coopersurgical, Inc.

> District Court, N.D. Texas · October 23, 2024

URL: https://www.frixlaw.com/law-library/cases/10672513

## Case

- **Court:** District Court, N.D. Texas
- **Decided:** October 23, 2024
- **Opinion:** 100trialcourt
- **Cited by:** 0 later opinions in the Frix Law Library

## Citator (automated)

- No negative treatment found by the automated citator. That is not the same as a confirmation that the case is good law; read the citing cases.
- Full citator and citing cases: https://www.frixlaw.com/law-library/cases/10672513

## How later opinions describe it (automated extraction)

- discussing waiver and preservation of a personal jurisdiction defense

## Opinion text

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF TEXAS
AMARILLO DIVISION

JULIA ANN RIDDLEY, §
§
Plaintiff, §
§
v. § 2:24-cv-109-BR
§
COOPERSURGICAL, INC. et al., §
§
Defendants. §

MEMORANDUM OPINION AND ORDER GRANTING IN PART
AND DENYING IN PART DEFENDANTS’ MOTIONS TO DISMISS

Before the Court are Motions to Dismiss filed by Defendants CooperSurgical, Inc.
(“CooperSurgical”), (ECF 7), Femcare, Ltd. – UK Subsidiary of Utah Medical Products, Inc.
(“Femcare”), (ECF 9), and Utah Medical Products, Inc. (“UTMD”), (ECF 12). The motions have
been fully briefed, and after due consideration the Court finds that they should be GRANTED IN
PART and DENIED IN PART. The Court holds that venue is proper in this division, that all
Defendants are subject to the specific personal jurisdiction of the Court at this stage of proceedings,
and that Plaintiff’s claims for design defect (Count 1), manufacturing defect (Count 2), and strict
liability (Count 4, construed as a claim for marketing defect) should be dismissed, but that
Plaintiff’s claims for failure to warn (Count 3), negligence (Count 5), violation of consumer
protection laws (Count 6), and gross negligence (Count 7) should be allowed to proceed against
all Defendants.1 Any motion by Plaintiff for leave to amend in the interest of repleading causes of
action dismissed by this Order shall be filed on or before December 2, 2024.

1 Although Plaintiff pleads “Exemplary Damages” as Count 8, the Court does not view damages as a separate cause
of action, and so does not treat Count 8 apart from Plaintiff’s gross negligence cause of action (Count 7).
I. Procedural Background
Plaintiff filed this action to recover under Texas law for damages allegedly resulting from
the use of Filshie Clips, a medical device used in tubal ligation surgeries. (ECF 1). In 2009,2
Plaintiff underwent such a surgery using Filshie Clips intended to permanently prevent future

pregnancy. (Id. at ¶¶ 29-32). In 2022, Plaintiff discovered that she was pregnant despite the tubal
ligation. (Id. at ¶¶ 33 & 34).
Plaintiff initially filed her lawsuit in the 320th District Court in Potter County, Texas, and
Defendants removed the case to this Federal Court pursuant to 28 U.S.C. § 1446. (ECF 1).
Plaintiff’s Petition asserts the same seven substantive causes of action against all three Defendants,
plus a plea for punitive damages (Count 8). (ECF 1-1 at ¶¶ 49-143). The substantive counts are:
(1) design defect, (2) manufacturing defect, (3) failure to warn, (4) strict liability, (5) negligence,
(6) violation of consumer protection laws, and (7) gross negligence. (Id.).
Each Defendant seeks dismissal of all claims. CooperSurgical moves the Court “to dismiss
Plaintiff’s lawsuit for lack of personal jurisdiction, improper venue, and for failure to state a claim
pursuant to Rule 12(b)(6) of the Federal Rules of Civil Procedure.” (ECF 83 at 5). Similarly,

Femcare and UTMD move the Court to dismiss “for lack of personal jurisdiction and for failure
to state a claim pursuant to Rules 12(b)(2) and 12(b)(6).” (ECF 10 at 6, internal punctuation
omitted, and ECF 13 at 7). Standards applicable to these grounds for dismissal—(A) improper
venue, (B) lack of personal jurisdiction, and (C) failure to state a claim—are detailed below, and
then applied to the facts of this case as pleaded by Plaintiff.

2 All facts referenced in this Order are drawn from Plaintiff’s state-court Petition (sometimes referred to herein as “the
Complaint”) or from admissions by one or more Defendants and are assumed to be true for the limited purpose of
evaluating the merits of the Motions.
3 Though the only ground for relief listed in CooperSurgical’s Motion, (ECF 7), is failure to state a claim subject to
Rule 12(b)(6), the Court will also address personal jurisdiction and venue as they relate to CooperSurgical because
they are mentioned in that Defendant’s Brief in Support, (ECF 8).
II. Legal Standards
Rule 12(b) of the Federal Rules of Civil Procedure establishes multiple defenses that may
be asserted by a motion before responding to a pleading in federal courts. Fed. R. Civ. P. 12(b).
Each of the three grounds for dismissal urged by the Defendants is established by a subsection of

Rule 12(b): improper venue by 12(b)(3), lack of personal jurisdiction by 12(b)(2), and failure to
state a claim by 12(b)(6). Fed. R. Civ. P. 12(b)(2)-(3), (6).
When motions under these rules depend on the facts of the case, the plaintiff bears the
burden of alleging those facts. See Umphress v. Hall, 479 F. Supp. 3d 344, 348 (N.D. Tex. Aug.
14, 2020) (collecting Fifth Circuit district court decisions that the plaintiff bears the burden of
proving proper venue to overcome a 12(b)(3) motion) and Revell v. Lidov, 317 F.3d 467, 469 (5th
Cir. 2002) (“The plaintiff bears the burden of establishing jurisdiction” to defeat a 12(b)(2)
motion); see also Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) and Ashcroft v. Iqbal, 556
U.S. 662, 678 (2009) (together setting the standard for a plaintiff’s factual allegations to survive a
12(b)(6) motion). However, because these motions must be resolved at the outset of a case, before

discovery is completed and findings of fact are made, the burden is a comparatively light one. A
plaintiff does not need to prove their case, but rather only to properly plead it.
To determine whether a plaintiff has met this burden, a court must view all well-pleaded
facts in the light most favorable to the plaintiff. See Ambraco Inc. v. Bossclip B.V., 570 F.3d 233,
237-8 (5th Cir. 2009) (cert. denied, 558 U.S. 1111 (2010)) (regarding 12(b)(3) motions); Carmona
v. Leo Ship Mgmt., 924 F.3d 190, 193 (5th Cir. 2019) (regarding 12(b)(2) motions); and Hodge v.
Engleman, 90 F.4th 840, 843-4 (5th Cir. 2024) (regarding 12(b)(6) motions). The sources to which
a court may look for facts depend on the motion in question.
A. Dismissal for Improper Venue
The Federal Rules of Civil Procedure allow defendants to challenge a claim by motion
asserting that the claim is being heard in an improper venue. Fed. R. Civ. P. 12(b)(3). Inter alia,

venue is proper in “a judicial district in which a substantial part of the events or omissions giving
rise to the claim occurred.” 28 U.S.C. § 1391(b)(2). If the case falls into this category, or one of
its alternatives, “venue is proper; if it does not, venue is improper, and the case must be dismissed
or transferred.” Atl. Marine Constr. Co. v. U.S. Dist. Ct. for W. Dist. Of Tex., 571 U.S. 49, 56
(2013).
In making this determination, a court may “consider more than just [the d]efendants’
conduct with regard to the events and omissions at issue in [the] case. That is, a court may also
consider the location of the effects of the alleged conduct.” Umphress, 479 F. Supp. 3d at 352. In
other words, if either a substantial part of (1) the relevant acts or omissions of the defendants, or
(2) the events resulting from those acts or omissions occurred in this judicial district, a motion to

dismiss or to transfer for improper venue should generally be denied. If necessary to resolve the
factual question of where the relevant events occurred, a court may look beyond the pleadings,
including to evidence submitted by a defendant with their motion or by a plaintiff with their
response. Id. at 348; accord Ambraco, 570 F.3d at 237-8.
B. Dismissal for Lack of Personal Jurisdiction
The Federal Rules of Civil Procedure also allow for a case to be dismissed for lack of
personal jurisdiction over a defendant. Fed. R. Civ. P. 12(b)(2). A defendant must raise this defense
in its answer or in a pre-answer motion, or else it will be deemed to have waived the defense and
voluntarily submitted to the court by future participation in the litigation. Fed. R. Civ. P.

12(h)(1)(B); see Mullins v. TestAmerica, Inc., 564 F.3d 386, 398-400 (5th Cir. 2009) (discussing
waiver and preservation of a personal jurisdiction defense). See also Fed. R. Civ. P. 81(c)(2)
(establishing the deadlines for defendants to answer or make pre-answer motions in a case that was
removed to federal court before that defendant filed a state-court answer).4
A court may only exercise personal jurisdiction over a defendant when permitted to do so

by both the long-arm statute of the forum State and by the constitutional requirements of due
process. See, e.g., Carmona, 924 F.3d at 193-4. In Texas, because the applicable long-arm statute
reaches to the furthest extent constitutionally permissible, these two requirements collapse into a
single inquiry. Id. at 193.
There are two kinds of personal jurisdiction that a court may assert over a defendant in
keeping with due process requirements: general and specific. See Bristol-Myers Squibb Co. v.
Superior Ct. of Calif., 582 U.S. 255, 261-3 (2017). There are some defendants over which a given
forum will always have personal jurisdiction, such that those defendants can always be sued in that
forum, no matter where the facts of the case occurred. See, e.g., Ford Motor Co. v. Mont. Eighth
Judicial Dist. Ct., 592 U.S. 351, 358-9 (2021). General personal jurisdiction of this sort is difficult

to establish and is not at issue in this case.
At issue in this case is the more restricted variety: specific personal jurisdiction. Unlike
general personal jurisdiction, a court’s specific personal jurisdiction over a defendant will extend
only to a specific set of claims. See Ford Motor Co., 592 U.S. at 359 (courts in “the forum State
may exercise [specific personal] jurisdiction in only certain cases”). These claims must “arise out
of or relate to the defendant’s contacts with the forum.” Id. (citing Bristol-Myers, 582 U.S. at 262,
and collecting cases) (internal punctuation omitted). And those contacts that give rise to the case

4 Plaintiff has not challenged the timeliness of the Notice of Removal in this case, nor of Defendants’ Motions to
Dismiss. The Court notes that all three Motions were filed on the seventh day after the Notice of Removal, making
them timely under Fed. R. Civ. P. 81(c)(2)(C).
must also constitute a “purposeful availment” by the defendant of the “privilege of conducting
activities within the forum State.” Ford Motor Co., 592 U.S. at 359. “The guiding principle of
specific personal jurisdiction is whether the defendant’s conduct and connection with the forum
State are such that he should reasonably anticipate being haled into court there.” Shambaugh &

Son, L.P. v. Steadfast Ins. Co., 91 F.4th 364, 372 (5th Cir. 2024) (quoting World-Wide Volkswagen
Corp. v. Woodson, 444 U.S. 286, 287 (1980)) (internal punctuation omitted).
The Fifth Circuit has articulated this standard as a three-prong test. If (1) the defendant has
“purposely directed its activities toward the forum State or purposely availed itself of the privileges
of conducting activities there” to the extent that establishes the necessary contacts between the
defendant and the forum, and (2) the plaintiff’s claim “arises out of or” relates to5 “the defendant’s
forum-related contacts,” and (3) the exercise of personal jurisdiction in the case would be fair and
reasonable, then the defendant will be subject to the specific personal jurisdiction of the forum.
Shambaugh & Son, 91 F.4th at 372 (citing E. Concrete Materials, Inc. v. ACE Am. Ins. Co., 948
F.3d 289, 296 (5th Cir. 2020)).

The burden to meet the first two prongs is on the plaintiff, and the burden to defeat the third
is on the defendant. Id. The plaintiff’s burden at this stage in the pleadings, as stated above, is not
to prove the facts underlying the case, but is rather to “make a prima facie showing that personal
jurisdiction is proper.” Id. at 369 (citing E. Concrete Materials, 948 F. 3d at 295). In determining
whether a plaintiff has met this threshold, a court may consider evidence submitted by the parties,
but either must resolve any factual conflicts pursuant to an evidentiary hearing or else must treat
all facts in the light most favorable to the plaintiff. Id.; see also Irving v. Owens-Corning Fiberglas

5 Though the Fifth Circuit here uses the phrase, “arises out of or results from,” they elsewhere in the same opinion use
the phrase “arise out of or relate to.” Shambaugh & Son, 91 F.4th at 375. As discussed below, the Supreme Court has
made clear that the test is not exclusively a causal one. Ford Motor Co., 592 U.S. at 361-2.
Corp., 864 F.2d 383, 384-5 (5th Cir. 1989) (discussing a district court’s reliance on affidavits and
depositions to resolve a Rule 12(b)(2) motion).
The first prong, as explained above, is to allege sufficient minimum contacts to support a
finding that the defendant has made a purposeful availment of the forum State, and the second

prong is to allege that the plaintiff’s claims are sufficiently connected to those contacts. The
connection in question does not need to be a causal relationship; it may suffice, for example, that
a company “serves a market for a product in the forum State and the product malfunctions there,”
even if the particular product that malfunctions wasn’t purchased at the market in the forum state.
Ford Motor Co., 592 U.S. at 361-2. There must, however, be a sufficient affiliation between the
defendant’s forum-directed activities and the plaintiff’s claim, such that the defendant should
reasonably anticipate being haled into the courts of that State, in connection with those activities,
on charges related to the plaintiff’s claims. Shambaugh & Son, 91 F.4th at 372.
If a plaintiff achieves a prima facie showing that the defendant has the necessary contacts
with the forum and that the plaintiff’s claims arise out of or relate to those contacts, then the

defendant must make a “compelling case” that exercise of specific personal jurisdiction would be
unfair or unreasonable. Nuovo Pignone, SpA v. STORMAN ASIA M/V, 310 F.3d 374, 382 (5th Cir.
2002). There are traditionally five factors that influence this determination: “(1) the burden on the
nonresident defendant, (2) the forum State’s interests, (3) the plaintiff’s interest in securing relief,
(4) the interest of the interstate judicial system in the efficient administration of justice, and (5) the
shared interest of the several States in furthering fundamental social policies.” E. Concrete
Materials, 948 F. 3d at 298; see also World-Wide Volkswagen, 444 U.S. at 292. The weightiest of
these factors is the first, the burden on the defendant. E. Concrete Materials, 948 F.3d at 299 (citing
Bristol-Myers, 582 U.S. at 263). However, that factor is not always determinative. As the Supreme
Court has stated,
“Restrictions on personal jurisdiction are more than a guarantee of immunity from
inconvenient or distant litigation. They are a consequence of territorial limitations
on the power of the respective States…Even if the defendant would suffer minimal
or no inconvenience from being forced to litigate before the tribunals of another
State; even if the forum has a strong interest in applying its law to the controversy;
even if the forum State is the most convenient location for litigation, the Due
Process Clause, acting as an instrument of interstate federalism, may sometimes act
to divest the State of its power to render a valid judgement.” Bristol-Myers, 582
U.S. at 263 (cleaned up).

In summary, when a defendant raises the defense of lack of personal jurisdiction in a pre-
pleading motion to dismiss, they thereby preserve the right to raise that defense in subsequent
proceedings, including in their answer, in motions for summary judgment, and at trial. To defeat
such a motion to dismiss, a plaintiff must, with all evidence viewed in the light most favorable to
them, make a prima facie case that the defendant in question had sufficient purposeful contacts
with the forum and that the cause of action arises out of or relates to those contacts. If the plaintiff
does so, the defendant must in turn make a compelling case that the five factors above would make
it unfair or unreasonable to exercise personal jurisdiction over them in the case at hand. If the
defendant fails to make such a compelling case, the motion to dismiss must be denied.
C. Dismissal for Failure to State a Claim
Finally, the Federal Rules of Civil Procedure allow for dismissal of a complaint when that
complaint fails to state a claim for which relief can be granted. Fed. R. Civ. P. 12(b)(6). To defeat
such a motion, a claim must first satisfy the standards of Rule 8 as those standards have been
articulated in past jurisprudence. See Fed. R. Civ. P. 8(a) and Iqbal, 556 U.S. at 678-80
(articulating the plausibility standard associated with Rule 8).
At bottom, a pleading needs “a short and plain statement of the claim showing that the
pleader is entitled to relief, in order to give the defendant fair notice of what the claim is and the
grounds upon which it rests.” Twombly, 550 U.S. at 555. Further, the “complaint must contain
sufficient factual matter, accepted as true, to state a claim to relief that is plausible on its face.”

Hodge, 90 F. 4th at 843 (quoting Iqbal, 556 U.S. at 678) (internal quotation marks omitted).
This determination involves a two-step process. See Waller v. Hanlon, 922 F.3d 590, 599
(5th Cir. 2019); see also Iqbal, 556 U.S. at 679. The first step is to set aside any “conclusory
allegations, unwarranted factual inferences, or legal conclusions” made by the plaintiff, which a
court cannot assume to be true in ruling on a 12(b)(6) motion. Hodge, 90 F. 4th at 843, and Waller,
922 F.3d at 599. The second step is to determine whether sufficient allegations remain in the
complaint for the court to reasonably infer that the plaintiff’s case is plausible, rather than merely
possible. Waller, 922 F.3d at 599 (citing Iqbal, 556 U.S. at 678-9).
Even if a complaint satisfies this Rule 8 standard as to its form and factual plausibility, it
may still fail to state a claim for which relief can be granted, such that dismissal pursuant to a Rule

12(b)(6) motion is warranted. Body by Cook, Inc. v. State Farm Mut. Auto. Ins., 869 F.3d 381,
385-6 (5th Cir. 2017). This is the case when the complaint is legally insufficient, because the
plaintiff “would not be entitled to relief under any set of facts or any possible theory that it could
prove consistent with the complaint’s allegations.” Id. at 386. A complaint will be dismissed unless
it states one or more claims that are each factually and legally sufficient.
A claim might be factually sufficient but legally insufficient, for example, if it asserts and
properly pleads a state-law claim that has been preempted by federal law. It is well-established
that state laws that conflict with federal laws have no effect. U.S. Const., Art. VI, cl. 2 (the
“Supremacy Clause”); see, e.g., Mut. Pharm. Co. v. Bartlett, 570 U.S. 472, 479-480 (2013). A
federal law might preempt a state law expressly, as by a provision that “States shall not establish”
any law of a certain kind, or it might preempt a state law impliedly by directly contradicting that
state law, like when a federal and a state law impose mutually incompatible duties and an actor
cannot simultaneously comply with both. Id. at 480. If a claim is legally insufficient for this or any

other reason, then it will be dismissed. This is true even if the claim has otherwise satisfied the
standards applicable to 12(b)(6) motions, because no relief can be granted for a legally insufficient
claim.
A Rule 12(b)(6) motion to dismiss must clear a high threshold before it can be granted.
See, e.g., Hodges, 90 F.4th at 843 (“Rule 12(b)(6) motions are viewed with disfavor and rarely
granted.”) (cleaned up). A court must consider all relevant matters in the light most favorable to
the plaintiff. Any allegations or evidence asserted by the movant, unless also contained in the
complaint, must be excluded from consideration. If any such matter is not excluded, the court must
convert the motion to one for summary judgment under Federal Rule of Civil Procedure 56, which
requires prior notice to the parties and sufficient opportunity for the plaintiff to respond to the

allegations or evidence submitted by the movant. Id.
To determine whether the Motions presently before the Court clear this threshold requires
analysis of two further groups of legal standards. First is the express and implied preemption of
state laws by the federal Medical Device Amendments to the Food, Drug, and Cosmetic Act.
Second is the set of legal standards controlling each of Plaintiff’s substantive state-law claims. For
efficiency, these standards are presented below, alongside application of the law to the instant case.
III. Analysis
Applying the standards articulated above, and for reasons explained below, the Court finds
first that this venue is proper for the resolution of this matter, and that all Defendants are properly
subject to the personal jurisdiction of this Court at this stage in the proceedings. Regarding
dismissal for failure to state a claim, the Court finds that Counts 1, 2, and 4 of Plaintiff’s Complaint,
for Design Defect, Manufacturing Defect, and Strict Liability (construed as a claim for Marketing
Defect), fail to state a claim for which relief can be granted, and so should be dismissed. Those

remaining, Counts 3, 5, 6, and 7, are sufficiently pleaded to survive Defendants’ Motions to
Dismiss.
After striking all conclusory allegations6 and unwarranted inferences from Plaintiff’s
Complaint, the Court relies on the following relevant factual assertions in making the holdings
below. CooperSurgical is a Delaware corporation with its principal place of business in
Connecticut. (ECF 1-1 at ¶ 4). CooperSurgical also maintains an office and a warehouse in
Stratford, Texas. (Id. at ¶ 8). UTMD is a Utah corporation with its principal place of business in
Utah, and Femcare is a wholly-owned subsidiary of UTMD based in the United Kingdom. (Id. at
¶¶ 5-6).
Each of the Defendants is involved in the manufacture, sale, and distribution of Filshie

Clips. (Id. at ¶ 14). Filshie Clips are used to accomplish tubal ligations by surgical implantation at
the fallopian tubes. (Id. at ¶¶ 15-16). Filshie Clips have been used this way in the United States
since they received Pre-Market Approval (“PMA”) from the FDA in 1996. (Id. at ¶¶ 17-18). The
FDA conditioned PMA on compliance with various requirements, including an obligation to
monitor and report adverse events attributable to the use of Filshie Clips. (Id. at ¶ 19).

6 The Court notes that Plaintiff repeatedly conditions her allegations that Defendants violated state law, limiting to
those claims to the extent that Defendants violated “parallel” federal law. (See ECF 1-1 at ¶¶ 28(a)-(g), 67, 75, 76, 90,
106, 116). As Plaintiff points out in the Responses to each of Defendants’ Motions, this was clearly the result of
careful drafting, (ECF 24 at 1, 6; ECF 26 at 1; and ECF 28 at 1, 8). However, the Court further notes that whether a
state-law duty parallels a federal duty is a question of law; consequently, Plaintiff’s assertions on this point are not
entitled to deference.
The FDA granted PMA for Filshie Clips while under the impression that they had a 0.13%
incidence rate of migrating from the site of their application. (Id. at ¶ 23). At the time of PMA, and
in the times since, Defendants have had actual knowledge that the incidence rate of migration is
much higher, as high as 25%. (Id. at ¶¶ 24, 30, 54). Defendants have not reported this increased

migration rate to either the FDA, healthcare providers, or end users. (Id. at ¶¶ 27, 36, 41, 54).
Plaintiff underwent a tubal ligation surgery involving Filshie Clips in Amarillo, Texas in
2009. (Id. at ¶ 29). In June of 2022, still in Amarillo, Texas, Plaintiff discovered that she had
become pregnant despite the surgery. (Id. at ¶ 33). It is inferred that one or both Filshie Clips used
in Plaintiff’s surgery have migrated from their site of application, or else this pregnancy would not
have occurred. (See id. at ¶ 34).
A. Venue is Proper
Because Plaintiff’s surgery using Filshie Clips and Plaintiff’s unexpected pregnancy both
occurred in Amarillo, Texas, where this Court is located, a substantial portion of the effects

resulting from the acts and omissions of the Defendants occurred in this judicial district.
Accordingly, the Court holds that venue is proper for this case, and to the extent Defendant
CooperSurgical’s Motion seeks dismissal or transfer for improper venue, that Motion is DENIED.
B. Defendants are Subject to Specific Personal Jurisdiction
Plaintiff has made the requisite prima facie showing that exercise of personal jurisdiction
by this Court would be proper with respect to all Defendants, and no Defendant has responded
with the requisite showing that such exercise at this stage of the case would be unfair or
unreasonable. The Court notes that Defendants have preserved the matter by raising lack of
personal jurisdiction in these Motions, and will have opportunities to raise the defense again at

future stages of this litigation, where the different legal standards might lead to different results.
1. CooperSurgical is Subject to Specific Personal Jurisdiction
Because Defendant CooperSurgical maintains an office and a warehouse in the State of
Texas, from which it may be reasonably inferred that CooperSurgical distributes and sells products
within Texas, CooperSurgical has purposely availed itself of the privilege of conducting activities

in this State to an extent that establishes the minimum contacts necessary for specific personal
jurisdiction.
For the limited purpose of determining personal jurisdiction over CooperSurgical, the
Court relies on allegations by Plaintiff, (ECF 24 at 20), Femcare, (ECF 11, “Declaration of Paul
Hill,” at 2, ¶ 7), and UTMD, (ECF 13 at 11), that are nowhere directly contradicted by
CooperSurgical. Specifically, these allegations are that CooperSurgical sells and distributes Filshie
Clips, and was the exclusive entity authorized to do so in the United States at the time of Plaintiff’s
surgery. Viewing these facts in the light most favorable to the Plaintiff, it is reasonable to infer
that CooperSurgical distributed the clips used in Plaintiff’s surgery from its Texas-based
warehouse, or else from its generalized sale and distribution of Filshie Clips in the State, such that

the Plaintiff’s claims would arise directly out of CooperSurgical’s contacts with the State.
Accordingly, and because CooperSurgical has not made the requisite showing that
subjecting it to the personal jurisdiction of this Court at this stage of the case would be unfair or
unreasonable, the Court holds that CooperSurgical is subject to specific personal jurisdiction in
this matter. To the extent CooperSurgical’s Motion seeks dismissal for lack of personal
jurisdiction, that Motion is DENIED.
2. Femcare is Subject to Specific Personal Jurisdiction
For the limited purpose of determining personal jurisdiction over Femcare, the Court, in
addition to the relevant facts listed above, relies on the following facts either asserted by Plaintiff
or admitted by Femcare. Femcare is now, and has been since at least 1996, the primary
manufacturer of Filshie Clips. (ECF 24 at 13). It can be reasonably inferred that Femcare
manufactured the clips used in Plaintiff’s surgery.
Femcare was the original entity to receive PMA from the FDA to sell Filshie Clips in the

United States. (Id.). Femcare originally established a joint venture for the exclusive purpose of
such sale and distribution, and that joint venture was later sold (with associated exclusive
distribution rights) to Defendant CooperSurgical. (Id. at 13-14). After the sale of distribution
rights, Femcare continued to exert significant influence over the marketing, sale, and distribution
of Filshie Clips in the United States. (Id. at 14). This influence included the provision of
promotional materials, the advance authorization of representations regarding the product, and the
direct assistance by Femcare employees in the marketing of the products. (Id.).
Femcare argues that these activities do not amount to purposeful availment of the privilege
of conducting business in the State of Texas. (ECF 34 at 11). To hold otherwise, according to
Femcare, would be to endorse the controversial opinion that merely placing products into the

“stream of commerce with the expectation that they will be purchased by consumers in the forum
state” may establish sufficient minimum contacts to support specific personal jurisdiction. (Id.);
cf. World-Wide Volkswagen, 444 U.S. at 298. As Femcare acknowledges, though Supreme Court
Justices have repeatedly expressed their dissatisfaction with it, no binding precedent has rejected
this “stream of commerce” test. (ECF 34 at 11-12). The Court does not find it necessary to either
endorse or reject the “stream of commerce” test in order to deal with the instant Motions.
Plaintiff has made a prima facie case that Femcare intentionally directed its business
activities at Texas, among other states, and that her case arises out of these contacts. Femcare has
not made the requisite showing that subjecting it to personal jurisdiction in Texas at this stage in
the case would be unduly burdensome or would threaten the shared interests of Texas, the United
States, and the United Kingdom in furthering fundamental social policies. Accordingly, the Court
holds that Femcare is properly subject to specific personal jurisdiction at this stage of proceedings;
thus, to the extent that Femcare’s Motion seeks dismissal for lack of personal jurisdiction, that

Motion is DENIED.
3. UTMD is Subject to Specific Personal Jurisdiction
For the limited purposes of determining personal jurisdiction over UTMD, the Court, in
addition to the relevant facts listed above, relies on the following facts either asserted by Plaintiff
or admitted by UTMD. UTMD acquired Femcare in 2011 and purchased rights to distribute Filshie
Clips in the United States from CooperSurgical in 2019. (ECF 13 at 11). Since 2019, UTMD has
marketed, sold, and distributed Filshie Clips in Texas. (ECF 26 at 19). UTMD was involved in the
decision to update the safety materials provided to users of Filshie Clips in 2021. (Id. at 20-21).
As a threshold matter, these activities amount to a deliberate availment of the privilege of
doing business in Texas, such that the minimum necessary contacts to establish specific personal

jurisdiction are present. UTMD urges, however, that these contacts are irrelevant to Plaintiff’s
claim, because they did not arise until after Plaintiff’s surgery. (ECF 33 at 11-14). UTMD points
to persuasive authority behind this position, including Moore’s Federal Practice and a published
First Circuit decision from 2005. (ECF 33 at 11-12). In light of the Supreme Court’s decision in
Ford Motor Co., however, UTMD’s arguments are insufficient to compel dismissal for lack of
personal jurisdiction at this stage in the case.
Ford Motor Co. made it clear that the required connection between a defendant’s forum
contacts and a plaintiff’s claims need not entail a causal relationship; rather, the defendant’s
contacts must result in a reasonable anticipation of being justifiably haled into the forum to defend
against claims like those brought by plaintiff. See Ford Motor Co., 592 U.S. at 361-2. It may well
be later found that UTMD’s forum-related activity does not make it liable to Plaintiff for her
injuries; the question presently before the Court is not whether UTMD is liable in this case, but
whether UTMD’s Texas-directed activities would ever permit the Court to hold it liable if those

activities resulted in injuries like those alleged by the Plaintiff.
Finally, the Court notes that the parties have extensively disputed the proper
characterization of UTMD’s relationship with Femcare. (ECF 13 at 15, ECF 26 at 15-26, & ECF
33 at 15-17). Though the matter may reappear at subsequent stages of the litigation, the Court is
able to resolve the request for dismissal for lack of personal jurisdiction without deciding the
question of whether Femcare is an alter ego of UTMD, and so makes no findings or holdings on
that question at this time.
Plaintiff has made a prima facie case that (1) UTMD intentionally avails itself of the
privilege of conducting activities in Texas and (2) Plaintiff’s claims sufficiently relate to those
activities, and UTMD has not responded with a compelling case that subjecting it to personal

jurisdiction in Texas would be unduly burdensome or would threaten the shared interests of the
several states in furthering fundamental social policies. Accordingly, UTMD is properly subject
to specific personal jurisdiction at this stage of proceedings; thus, to the extent that UTMD’s
Motion seeks dismissal for lack of personal jurisdiction, that Motion is DENIED.
C. Some of Plaintiff’s Claims Do Not Survive Dismissal
As noted above and for reasons explained below, the Court finds that Counts 1, 2, and 4 of
Plaintiff’s Complaint fail to state a claim for which relief can be granted, and should be dismissed.
Counts 3, 5, 6, and 7 are sufficiently pleaded to survive Defendants’ Motions to Dismiss. The
explanation for this holding requires analysis of two particular groups of legal standards. We look
first to the preemption of state laws by the federal Medical Device Amendments to the Food, Drug,
and Cosmetic Act, and then to each of Plaintiff’s particular state-law claims and their requirements.
1. Preemption Under the MDA
In 1938, Congress passed the Food, Drug, and Cosmetic Act (“FDCA”), now codified at

21 U.S.C. § 301 et seq., to broaden existing federal regulations on food, drugs, medical devices,
and cosmetics. See Medtronic Inc. v. Lohr, 518 U.S. 470, 475-476 (1996). In 1976, the Medical
Device Amendments (“MDA”) to the FDCA, codified at 21 U.S.C. § 360c et seq., further
expanded regulatory coverage over medical devices. Id. at 476-77; see also Riegel v. Medtronic,
Inc., 552 U.S. 312, 315-17 (2008).
As a result of the MDA, the state-law regimes that had previously governed the
introduction of medical devices for human use were generally supplanted and replaced with a
comprehensive program of federal oversight. The primary mechanism of that replacement was an
express pre-emption provision providing:
“No State or political subdivision of a State may establish or continue in effect with
respect to a device intended for human use any requirement
(1) which is different from, or in addition to, any requirement applicable under
this chapter to the device, and
(2) which relates to the safety or effectiveness of the device or to any other
matter included in a requirement applicable to the device under this
chapter.” 21 U.S.C. § 360k(a).7

The Supreme Court examined this express preemption provision in Lohr, finding that it did
not automatically eliminate all common law duties enforceable by actions for damages under state
law. Lohr, 518 U.S. at 491. The Court revisited the provision in Riegel and clarified that it would
preempt some such duties if they imposed requirements on the device that were “different from,
or in addition to, federal requirements, and that related[d] to the safety or effectiveness of the

7 There is an exception established in 21 U.S.C. § 360k(b) that allows the FDA to empower state or local requirements
that meet certain standards. That exception is not at issue in this case.
device or to any other matter included in a [federal] requirement applicable to the device.” Riegel,
552 U.S. at 323.
To determine whether a particular state-law claim is barred by the MDA’s express
preemption provision, courts have distilled Supreme Court jurisprudence into a two-prong test.

Hughes v. Boston Scientific Corp., 631 F.3d 762, 767-8 (5th Cir. 2011). The first prong is whether
the FDA has set requirements for the device, such as by granting a business pre-market approval
to make and sell the device under certain circumstances. Id.; accord Riegel, 552 U.S. at 322. The
second prong is whether the state law giving rise to the claim imposes any requirements on the
device that differ from or are additional to the FDA’s requirements. Hughes, 631 F.3d at 768. A
state law claim will be dismissed if it imposes such requirements and the requirements relate to
the safety or effectiveness of the device, or to any matter otherwise regulated by federal
requirements. 21 U.S.C. § 360k(a)(2).
Even if a state law claim survives this two-prong test, it may still be impliedly preempted
by the MDA. As stated above, a state law is impliedly preempted by a federal law if it directly

conflicts with the terms of that federal law, such as when it would not be possible to simultaneously
satisfy the requirements of both. For example, suppose that the FDA required a device to be sold
with a particular label, and a plaintiff asserted a failure-to-warn tort claim against the marketer on
the sole grounds that the FDA-approved label inadequately disclosed a certain risk. See Bartlett,
570 U.S. at 475. In that case, it would be impossible for the marketer to simultaneously perform
the duty asserted by the plaintiff and the duty to use the FDA-approved label, so the plaintiff’s
claim would be impliedly preempted.
The FDCA also includes a provision that, though it does not expressly abrogate any
particular state laws, may imply preemption of a state law claim by barring suits to privately
enforce requirements imposed by the FDCA or MDA. 21 U.S.C. § 337(a) (“All such proceedings
for the enforcement, or to restrain violations, of this Act shall be by and in the name of the United
States.”). For example, if the hypothetical plaintiff above instead based their failure-to-warn claim
solely on the grounds that the marketer had deliberately concealed evidence of the risk from the

FDA during the pre-market approval process, their claim would conflict with 337(a) by attempting
to privately enforce FDCA procedures, and so would be impliedly preempted. See Buckman Co.
v. Plaintiff’s Legal Comm., 531 U.S. 341, 343-4 (2001).
Despite these multiple forms of preemption by the MDA, courts have been clear that the
law does not result in complete immunity for federally-regulated medical device companies. To
survive preemption, a claim based in state law must:
(1) exist independently of the MDA, such that the complained-of behavior
would still have violated state law even if the MDA had never been passed;8
(2) leave space for the defendant to have avoided liability under state law
without having breached federal law in the process,9 and

(3) impose no additional or differing requirements on a federally-regulated
device in the areas of safety, effectiveness, or any area covered by the
federal regulations.10
One shorthand summary of these elements is that a State may provide “a damages remedy
for claims premised on a violation of FDA regulations; the state duties in such a case ‘parallel,’
rather than add to, federal requirements. Therefore, an independent state-law duty may form the

8 Otherwise, the claim would be impliedly preempted by 337(a) as an attempt to privately enforce the Act. Hughes,
631 F.3d at 775.
9 Otherwise, the claim would be impliedly preempted by directly conflicting with the requirements of the FDA.
Bartlett, 570 U.S. at 479-80.
10 Otherwise, the claim would be expressly preempted by 360k(a). Riegel, 552 U.S. at 353-4.
basis of a tort claim for which violations of the FDCA may be presented as evidence of breach.”
Spano v. Whole Foods, Inc., 65 F.4th 260, 264 (5th Cir. 2023).
2. Standards Governing Plaintiff’s State-Law Claims
To determine which of Plaintiff’s state law claims may be preempted by the MDA requires

an analysis of the law controlling each claim, to find whether any of them, as a matter of law and
in light of the well-pleaded facts alleged in the Complaint,11 passes the tests articulated above. As
stated, the seven substantive claims at issue in this case are (1) design defect, (2) manufacturing
defect, (3) failure to warn, (4) strict liability, (5) negligence, (6) violation of consumer protection
laws, and (7) gross negligence.
i. Design Defect
Under Texas law, a products liability claim for design defect is grounded both in statute
and in the common law. Nester v. Textron, Inc., 888 F.3d 151, 156, n. 1 (5th Cir. 2018). To recover,
a plaintiff pleading design defect must show that “(1) the product was defectively designed so as
to render it unreasonably dangerous; (2) a safer alternative design existed; and (3) the defect was

a producing cause of the injury for which the plaintiff seeks recovery.” Goodner v. Hyundai Motor
Co., 650 F.3d 1034, 1040 (5th Cir. 2011); see also Tex. Civ. Prac. & Rem. Code § 82.005.
Whether a design is unreasonably dangerous is generally a question of fact, and courts
considering the question rely on a set of common-law factors to guide their analysis. Goodner, 650
F.3d at 1040. The ultimate purpose of these factors is to balance the benefit or utility of the product,
the probability and severity of injuries that might result from its use, and the costs that would be
borne by intended users, by the manufacturer, and by the public at as a whole if the product were
required to be adapted to a less dangerous design. Id.

11 As stated above, the Court sometimes refers to Plaintiff’s state-court Petition as her “Complaint,” so that the
terminology in this Opinion is consistent with federal law.
Similarly, a plaintiff must show as a matter of fact that an alternative design would have
reasonably reduced the risk of injury and was feasible as an alternative when the device left the
defendant’s control. Id. at 1042. In other words, to return a verdict for the plaintiff on a Texas
products liability claim for design defect, a trier would have to find that the product design was

dangerous in ways that were not justified by the utility of the product or by the economics of the
matter and that the product could have been designed in another, better way. To survive a Rule
12(b)(6) motion to dismiss, then, a plaintiff’s complaint must plausibly allege these facts (as well
as causation). See Rodriguez v. Am. Med. Sys., Inc., 597 Fed. App’x 226, 230 (5th Cir. 2014)
(unpublished).
The parties have not pointed to, and the Court is not aware of, any directly controlling
precedent on the question of whether Texas design defect claims are preempted as a matter of law
for device designs that have received pre-market approval (“PMA”) under the MDA. The Court
notes, however, that the matters balanced by a Texas design defect decision (i.e., the risks and
benefits associated with the design as compared to potential alternatives) are exactly the matters

administratively adjudicated by the FDA when making a PMA determination under the MDA.
The Court holds that for a claim of strict liability for design defect under Texas law to
survive preemption by the MDA, the plaintiff must show that the product alleged to be defective
was designed in a manner differing from the design approved by the FDA. If the FDA has approved
the design actually used by the defendant to manufacture the product at issue, then to permit a
design defect claim to proceed would necessarily allow state law to impose requirements on the
device that add to or differ from those imposed by federal law. Accordingly, any claim that a
device was defectively designed despite compliance with the design standards established by the
FDA is necessarily preempted under the MDA. Accord Gomez v. St. Jude Med. Daig Div., Inc.,
442 F.3d 919, 929-30 (5th Cir. 2006).
ii. Manufacturing Defect
A products liability claim for manufacturing defect under Texas common law12 requires a
plaintiff to show that “a product deviates, in its construction or quality, from the specifications or

planned output in a manner that renders it unreasonably dangerous,” and that the deviation or
defect “existed at the time the product left the manufacturer’s possession” and was “a producing
cause of the plaintiff’s injuries.” Johnston v. Ferrellgas, Inc., 96 F.4th 852, 858 (5th Cir. 2024)
(cleaned up). These are generally factual questions, and significant emphasis is placed on avoiding
speculation and conclusory determinations. See id.
At the pleading stage, a plaintiff must allege sufficient facts to meet the Twombly
plausibility standard for these elements. See Bass v. Stryker Corp., 669 F.3d 501, 509 (5th Cir.
2012). Further, in contexts where the specifications for manufacturing a device are established by
the federal government under the MDA, the plaintiff must allege “manufacturing defects resulting
from violations of federal regulations.” Bass, 669 F.3d at 510. As always, the plaintiff need not

prove these facts to defeat a Rule 12(b)(6) motion, but must at least allege them sufficiently to
make their case facially plausible and more than speculative.
If a plaintiff’s well-pleaded facts pass the Iqbal-Twombly two-step standard, the Fifth
Circuit has explicitly held that a Texas manufacturing defect claim is not preempted by the MDA
as a matter of law. Bass, 669 F.3d at 509-510. If a plaintiff can show that a manufacturing process
failed in a manner that violated FDA requirements and produced a deviation in construction or

12 The Court notes that the Plaintiff’s state-court Petition associates this count with Chapter 82 of the Texas Civil
Practice and Remedies Code, but that statute has not modified the common-law cause of action for manufacturing
defect.
quality resulting in an unreasonably dangerous product, that plaintiff may be entitled to recover
damages under state law.
iii. Failure to Warn (Negligence)
Under Texas law, both manufacturers and product suppliers have a duty13 to warn of

dangers that they know or have reason to know are likely to apply to users who may not, absent
the warning, otherwise recognize those dangers. Garcia v. United States, 986 F.3d 513, 534-5 (5th
Cir. 2021); see also Bristol-Myers Co. v. Gonzales, 561 S.W.2d 801, 804 (Tex. 1978) (hereafter
“Gonzales” to avoid confusion with the personal jurisdiction case cited above). This duty may
sometimes be satisfied by providing the necessary warnings to intermediaries who can then be
relied on to relay those warnings to the final user. See Humble Sand & Gravel Inc. v. Gomez, 146
S.W. 3d 170, 172 (Tex. 2004). If a defendant breaches such a duty and thereby causes damages,
that defendant may be liable for negligent failure to warn.
Federal regulation under the MDA intersects with the applicable common-law14 elements
of negligent failure to warn in both the areas of duty and of causation. When receiving PMA for a

device, a manufacturer may be required to report adverse events to the FDA on an ongoing basis,
which imposes a specific duty that may parallel common-law duties imposed by state law. Hughes,
631 F.3d at 769-71. Additionally, FDA restrictions imposed on a device may impact the tort law
requirement of causation by restricting a company’s possible actions and interposing discretionary
agency decisions into hypothetical sequences of events. See Hughes, 631 F.3d at 776.
If a plaintiff’s well-pleaded facts carry a negligent failure to warn claim past the Iqbal-
Twombly two-step plausibility test, then that claim might not be preempted by the MDA, so long

13 Manufacturers may also be strictly liable for failure to warn if their product is unreasonably dangerous; this is
addressed below under Claim 4: Strict Liability.
14 Though Plaintiff’s state-court Petition associates Count 3 with Chapter 82 of the Texas Civil Practice and Remedies
Code, that statute does not control products liability claims for either negligent or strict-liability failure to warn.
as maintenance of the claim merely provides a damages remedy for a breach of a duty that also
violated federal law.
iv. Strict Liability (Marketing Defect)
In addition to the duty to report dangers of which a company knows or has reason to know,
Texas law may impose strict liability for failure to warn15 when the product in question is

unreasonably dangerous. See Humble Sand, 146 S.W.3d at 181, n. 17 & 18 (clarifying differences
between negligent and strict liability failure to warn claims). To sustain this claim, a plaintiff must
show (1) using the product involved a risk of harm, (2) the defendant knew or should have
reasonably foreseen the risk, (3) the defendant did not adequately warn of the risk or provide
instructions for safe use, (4) the lack of adequate warning made the product unreasonably
dangerous, and (5) the failure to warn caused the plaintiff’s damages. See Wright v. Ford Motor
Co., 508 F.3d 263, 275 (5th Cir. 2007) (hereafter “Wright” to avoid confusion with the personal
jurisdiction case cited above).
Unlike a claim for negligence, which focuses on the conduct of the defendant, a strict

liability claim focuses on the product itself, and in the context of a marketing defect claim, this
encompasses the warnings, labels, and instructions provided with the product. See Humble Sand,
146 S.W.3d at 181, and Bass, 669 F.3d at 515. The adequacy of warnings is generally a matter of
fact for determination by the jury.
Accordingly, a strict liability claim for marketing defect will be preempted by the MDA to
the extent that the claim imposes requirements for the marketing of a device that are different from
or additional to the requirements imposed by federal law. See Hughes, 631 F.3d at 768-9. As with

15 Though Plaintiff’s fourth claim was advanced under the heading of “strict liability” without qualification, and
though Texas law imposes strict liability in three situations—design defect, manufacturing defect, and marketing
defect—the first two of these have been independently asserted as Counts 1 & 2, so the Court construes Count 4 of
the state-court Petition as asserting a strict liability claim for marketing defect specifically.
strict liability for design defect or manufacturing defect, however, a marketing defect claim will
not be preempted to the extent it is premised on violations of the marketing requirements imposed
by the FDA. Id. at 769-70.
v. Negligence

Under Texas law, a claim for negligence in a products liability suit will be subsumed into
the plaintiff’s defective product claims unless the plaintiff has alleged some negligence unrelated
to the product being unreasonably dangerous when sold. Shaun T. Mian Corp. v. Hewlett-Packard
Co., 237 S.W.3d 851, 857 (Tex. App.--Dallas 2007, pet. denied). Unless so subsumed, whether a
negligence claim will survive a Rule 12(b)(6) motion depends primarily on whether it plausibly
alleges breach of a duty of care resulting in damages. If it clears facial plausibility, it will not
necessarily be preempted by the MDA; to the extent it merely provides a damages remedy for
violation of a state-law duty that parallels federal requirements, it will be allowed to proceed.
Spano, 65 F.4th at 264.
vi. Violation of Consumer Protection Laws

As explained by the Fifth Circuit,
“The Texas Deceptive Trade Practices & Consumer Protection Act [“DTPA”]16
protects a consumer from false, misleading, or deceptive acts or practices, from an
unconscionable action or course of action by any person, and from the breach of an
implied or express warranty in the conduct of any trade or commerce that is the
producing cause of actual damage. To sustain a claim under the Act, a plaintiff must
show that (1) the plaintiff was a consumer; (2) the defendant either engaged in false
misleading, or deceptive acts, or engaged in an unconscionable action or course of
action; and (3) the Act’s laundry-list violation or unconscionable action was a
producing cause of the plaintiff’s injury.” Huynh v. Walmart Inc., 30 F.4th 448, 453
(5th Cir. 2022) (cleaned up).

16 Though the Plaintiff’s state-court Petition alleges “violation of state and Federal consumer protection statutes,”
(ECF 1-1 at ¶ 119), the DTPA is the only specific grounds on which the Plaintiff alleges to be entitled to relief.
The DTPA, codified at Texas Business & Commerce Code § 17.41 et seq., non-
exhaustively lists many acts qualifying as “false, misleading, or deceptive,” including for example,
“representing that goods or services have…characteristics…uses, [or] benefits which they do not
have.” Tex. Bus. & Com. Code § 17.46(b)(5). The DTPA also defines an “unconscionable action”

as one that “to a consumer’s detriment, takes advantage of the lack of knowledge, ability,
experience, or capacity of the consumer to a grossly unfair degree.” Id. at § 17.45(5).
Whether a claim under the DTPA is preempted by the MDA depends on whether the claim
imposes requirements that are different from or additional to federal requirements. For example,
if a DTPA claim categorizes as “deceptive” actions that were explicitly approved by the FDA, that
claim will be preempted by federal law. If, however, a claim under the DTPA merely provides a
damages remedy for actions by the defendant that violated federal requirements, that claim will
not necessarily be preempted. Spano, 65 F.4th at 264.
vii. Gross Negligence
Under Texas law, a finding of gross negligence requires an act or omission that involves

an extreme degree of risk of which the actor was actually aware, but to which they were
consciously indifferent. Marsillo v. Dunnick, 683 S.W.3d 387, 392-3 (Tex. 2024) and Tex. Civ.
Prac. & Rem. Code § 41.001(11). The existence of the risk is an objective question of fact that
requires a likelihood of serious injury, over and beyond even a mere probability of minor harm.
Marsillo, 683 S.W.3d at 393. The actual knowledge of the plaintiff is a question of subjective fact,
and once such knowledge is established, the defendant’s acts or omissions can be taken as
demonstrations of the requisite conscious indifference. Id.
A claim for gross negligence does not necessarily impose any requirements on a federally-
regulated medical device. To the extent that a claim for gross negligence pursues a state-law-
permitted damages remedy for a duty that parallels federal requirements, and to the extent that
violations of the duty are also violations of the federal requirements, a gross negligence claim is
not preempted by the MDA. Spano, 65 F.4th at 264.
3. Application to Plaintiff’s Claims

For reasons set forth in order below, application of the standards articulated above to
Plaintiff’s claims, as pleaded in her state-court Petition, requires that her strict liability claims—
for design defect (Count 1), manufacturing defect (Count 2), and marketing defect (Count 4, as
construed by the Court) be dismissed for failure to state a claim that would survive preemption by
the MDA. Plaintiff’s other claims, however, are adequately pleaded and are not preempted as a
matter of law.
i. Design Defect
Plaintiff has not pleaded that the Filshie Clips used in her surgery or otherwise currently
distributed by the Defendants are designed in a manner other than that approved by the FDA.
Rather, Plaintiff has alleged that the FDA-approved design is itself unreasonably dangerous, and

has implied that the FDA would not have approved the design if they had found the incidence of
migration to be 25% rather than 0.13%. (ECF 1-1, ¶¶ 53-4). Because Plaintiff has asserted a claim
for design defect but has not alleged that the product in question was designed in violation of
federal standards, she has failed to plausibly state a claim for design defect that would avoid
preemption by the MDA. See St. Jude Med. Daig Div., Inc., 442 F.3d at 929-30. Accordingly, to
the extent that Defendants’ Motions seek dismissal of Count 1 of Plaintiff’s state-court Petition for
failure to state a claim upon which relief can be granted, those Motions are GRANTED.
ii. Manufacturing Defect
Plaintiff has not alleged that the process of manufacturing Filshie Clips has failed in any
manner that violates FDA standards. On the contrary, Plaintiff alleges that her injury is due to
dangerousness inherent in the product as designed and manufactured in the manner approved by

the FDA. (ECF 1-1, ¶¶ 53-4). Because Plaintiff has asserted a claim for manufacturing defect but
has not alleged that the product in question was manufactured in violation of federal standards, she
has failed to state a claim that would avoid preemption by the MDA. See Bass, 669 F.3d at 510.
Accordingly, to the extent Defendants’ Motions seek dismissal of Count 2 of Plaintiff’s state-court
Petition for failure to state a claim, those Motions are GRANTED.
iii. Failure to Warn (Negligence)
Plaintiff has alleged that Defendants had a common-law duty to warn of dangers associated
with the use of Filshie Clips in tubal ligation surgeries. Plaintiff has further alleged that Defendants
were aware of such a danger, that they could have discharged their duty by reporting the danger to
the FDA, and that by failing to do so they both breached their common-law duty and violated FDA

requirements. These allegations establish plausible grounds for a damages remedy that merely
parallels, and does not add to or differ from, federal requirements; accordingly, Plaintiff’s claim
for negligent failure to warn is not preempted by the MDA. Hughes, 631 F.3d at 769-71. Thus, to
the extent Defendants’ Motions seek dismissal of Count 3 of Plaintiff’s state-court Petition for
failure to state a claim, those Motions are DENIED.
iv. Strict Liability (Marketing Defect)
As mentioned above, Plaintiff has pleaded a claim for strict liability, and the Court
construes this Count as one for marketing defect specifically, because claims for design defect and
manufacturing defect were separately pleaded in Counts 1 and 2. Plaintiff does not allege that
Filshie Clips have been marketed in a manner that violates FDA requirements. On the contrary,
Plaintiff argues that the product marketing and the warnings, labels, and instructions provided with
the Filshie Clips were inadequate despite their compliance with federal requirements. (ECF 1-1, ¶
79). If Plaintiff’s claim were successful, it would necessarily involve state law imposing marketing

requirements on the Filshie Clips that were different from and additional to federal requirements,
so Plaintiff’s claim is preempted by the MDA. Hughes, 631 F.3d at 768-9. Accordingly, to the
extent Defendants’ Motions seek dismissal of Count 4 of Plaintiff’s state-court Petition for failure
to state a claim, those Motions are GRANTED.
v. Negligence
Plaintiff has pleaded negligence by the Defendants that resulted in Filshie Clips being
unreasonably dangerous when sold, but has also pleaded subsequent negligence by the Defendants
in failing to adequately warn of known dangers. Accordingly, Plaintiff’s claim for negligence is
not completely subsumed into her products liability claims. Further, the subsequent negligence
plausibly alleged by Plaintiff may have independently violated both federal law and parallel duties

imposed by state law. Accordingly, Plaintiff’s claim for negligence is sufficiently pleaded, and to
the extent Defendants’ Motions seek dismissal of Count 5 of Plaintiff’s state-court Petition for
failure to state a claim, those Motions are DENIED.
vi. Violation of Consumer Protection Laws
Plaintiff has alleged that Defendants knowingly withheld information about a significant
risk associated with their product, and that by doing so they violated both FDA-imposed
requirements and the Texas DTPA. (ECF 1-1 at ¶ 119). Because Plaintiff does not claim that
conduct authorized by the FDA is nevertheless prohibited under the DTPA, but instead seeks a
damages remedy under state law for conduct that also violated federal requirements, her claim is
not preempted by the MDA. Spano, 65 F.4th at 264. Accordingly, to the extent Defendants’
Motions seek dismissal of Count 6 of Plaintiff’s state-court Petition for failure to state a claim,
those Motions are DENIED.
vii. Gross Negligence

Finally, Plaintiff has alleged that Defendants had actual knowledge that the incidence rate
of migration from the site of application for their product was substantially higher than originally
reported, that this increased rate resulted in an extreme degree of risk, and that Defendants acted
with conscious indifference in reckless disregard of that risk. (ECF 1-1 at ¶ 130). Accordingly,
Plaintiff has sufficiently pled a facially plausible claim for gross negligence. Further, because
Plaintiff has alleged that the grossly negligent acts and omissions of Defendants also violated FDA
requirements, Plaintiff’s claim does not impose restrictions on Defendants or on Filshie Clips that
add to or differ from federal requirements, but instead seeks only a damages remedy under state
law that parallels federal law. Spano, 65 F.4th at 264. Accordingly, to the extent Defendants’
Motions seek dismissal of Count 7 of Plaintiff’s state-court Petition for failure to state a claim,

those Motions are DENIED.
The Court further notes that because Plaintiff’s claim for gross negligence survives
Defendants’ Motions to Dismiss, Plaintiff’s plea for exemplary damages (“Count 8” of Plaintiff’s
Petition) remains live in this proceeding. See Tex. Civ. Prac. & Rem. Code § 41.003(a)(3).
IV. Conclusion
In summary, the Court holds that venue is proper in this judicial district, and that all three
defendants—CooperSurgical, Femcare, and UTMD—are subject to the personal jurisdiction of the
Court at this stage of the pleadings. The Court further holds that Plaintiff’s strict liability claims
for design defect, manufacturing defect, and marketing defect are inadequately pleaded to survive
preemption by federal law.
For the foregoing reasons, CooperSurgical’s Motion to Dismiss, (ECF 7), Femcare’s
Motion to Dismiss, (ECF 9), and UTMD’s Motion to Dismiss, (ECF 12), are hereby GRANTED
IN PART and DENIED IN PART. Counts 1, 2, and 4 of Plaintiffs state-court Petition, (ECF 1-
1), are hereby DISMISSED without prejudice to repleading in connection with factual allegations
that would permit those claims to survive preemption by federal law. If Plaintiff wishes to so
replead, it is hereby ORDERED that she shall file a Motion for Leave to Amend on or before
December 2, 2024.'’ Counts 3, 5, 6, 7, and 8 shall be allowed to proceed against all three
Defendants.

IT IS SO ORDERED.
ENTERED October 23, 2024.

LEE es RENO
UNITED STATES MAGISTRATE JUDGE

The Court notes that under the current Scheduling Order in this case, Plaintiff has until May 12, 2025 to request
leave to file an Amended Complaint; the deadline established in the present Order controls only as regarding requests
to replead causes of action dismissed by this Order. The Court notes that leave will not be granted to replead dismissed
claims unless they are accompanied by factual allegations that would permit those claims to survive preemption by
federal law. Finally, the Court notes that nothing in this Order prohibits Plaintiff from requesting an extension of her
December 2, 2024 deadline if necessary; the Court will evaluate any such requests in light of the four good-cause
factors that control any Scheduling Order modification. (See ECF 41 at 1-2).
31

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/cases/10672513. Public record. Not legal advice.